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Pseudomonas aeruginosa is a major opportunistic human pathogen which employs a
myriad of virulence factors. In people with cystic fibrosis (CF) P. aeruginosa frequently
colonises the lungs and becomes a chronic infection that evolves to become less virulent
over time, but often adapts to favour persistence in the host with alginate-producing
mucoid, slow-growing, and antibiotic resistant phenotypes emerging. Cysteamine is an
endogenous aminothiol which has been shown to prevent biofilm formation, reduce
phenazine production, and potentiate antibiotic activity against P. aeruginosa, and has
been investigated in clinical trials as an adjunct therapy for pulmonary exacerbations of
CF. Here we demonstrate (for the first time in a prokaryote) that cysteamine prevents
glycine utilisation by P. aeruginosa in common with previously reported activity blocking
the glycine cleavage system in human cells. Despite the clear inhibition of glycine
metabolism, cysteamine also inhibits hydrogen cyanide (HCN) production by P.
aeruginosa, suggesting a direct interference in the regulation of virulence factor
synthesis. Cysteamine impaired chemotaxis, lowered pyocyanin, pyoverdine and
exopolysaccharide production, and reduced the toxicity of P. aeruginosa secreted
factors in a Galleria mellonella infection model. Thus, cysteamine has additional potent
anti-virulence properties targeting P. aeruginosa, further supporting its therapeutic
potential in CF and other infections.
Keywords: virulence, biofilm, Pseudomonas aeruginosa, novel therapeutic, glycine cleavage complexINTRODUCTION
Pseudomonas aeruginosa is a versatile and opportunistic human pathogen and often recalcitrant to
antibiotic therapy. It is a major cause of ventilator-associated pneumonia (VAP) in hospitals
(Koulenti et al., 2009), a less common cause of community acquired pneumonia (CAP) and can also
cause infections at other body sites such as wound infections, urinary tract catheter-associated
infections and gangrenous diabetic foot ulcer, (Gjødsbol et al., 2006; Nathwani et al., 2014; Trubiano
and Padiglione, 2015; Kim et al., 2020). Acute P. aeruginosa pneumonia can occur in
immunocompetent patients but susceptible and immunocompromised patients such as thosegy | www.frontiersin.org September 2021 | Volume 11 | Article 7182131
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most at risk. Cystic fibrosis (CF) patients have dysfunctional
mucocilliary clearance due to thick, dehydrated mucus, and are
at risk of lung colonisation by P. aeruginosa. Despite recent falls
in prevalence, it is still a common species found in the sputum of
adults with CF (Cystic Fibrosis Foundation Patient Registry:
2018 Annual Data Report, 2019). This Gram negative motile
rod-shaped bacterium was thought to be intrinsically resistant to
macrolide antibiotics, though recent evidence suggests that the
high minimal inhibitory concentrations (MICs) found in in vitro
susceptibility testing media were less reflective of antimicrobial
activity in physiological conditions (Buyck et al., 2012).
Nevertheless, the rising incidence of acquired resistance,
particularly to carbapenems has led to its designation as a
critical priority pathogen of concern by WHO (World Health
Organisation (WHO), 2017).
P. aeruginosa can produce a wide array of virulence factors,
such as phenazine pigments, as well as cytotoxins, exotoxins,
elastase, phospholipase C, and protease A (Azam and Khan,
2019). In CF, opportunistic isolates sometimes establish chronic
infection which can be very difficult to eradicate (Lyczak et al.,
2000; Gibson et al., 2003). During early infection P. aeruginosa
isolates are usually highly motile, express type III secretion
system effector molecules and the LPS O antigen. Adaptation
to chronic infection, often seen within the airways of adults with
CF, leads toward a mucoid phenotype, alginate production,
acquisition of antibiotic resistance and loss of motility (Smith
et al., 2006; Mowat et al., 2011). Evolutionary divergence and
adaptation to certain microenvironments can even take place
within specific parts of the CF lung (Winstanley et al., 2016). The
volatile, and highly toxic compound HCN can be detected in the
breath of people with CF colonised with P. aeruginosa (Gilchrist
et al., 2013; Gilchrist et al., 2015) and its presence in sputum
significantly correlates with poorer lung function in individuals
with CF and non-CF bronchiectasis (Ryall et al., 2008). Over
time, P. aeruginosa colonisation is associated with damage to the
lung architecture and declining lung function in CF (Kerem
et al., 2014). Most of the virulence traits of P. aeruginosa are
secreted factors under the control of complex, overlapping
quorum sensing systems which include those regulated by
LasR, RhlR, and MvfR (PqsR) transcriptional regulators.
Although these systems have been described as hierarchical
(with LasR system at the top) and interdependent (Pesci et al.,
1999; McGrath et al., 2004; Heeb et al., 2011), LasR loss of
function mutations often arise in chronic CF infections and both
RhlR and PQS can function independently (Kostylev et al., 2019).
Cysteamine is a simple aminothiol, produced endogenously
through the action of pantetheinases such as vanin-1 in the
metabolism of co-enzyme A (Pitari et al., 2000) and is a molecule
which may have an underappreciated role in immunity to
infection (Fraser-Pitt and Mercer, 2021). It is also a therapeutic
licensed for many years for the treatment of the lysosomal
storage disorder, cystinosis (Schneider et al., 1995). Cysteamine
may also have therapeutic potential as both an oral adjunct to
standard of care therapy (SOCT) during infectious exacerbations
in CF and as an inhaled maintenance therapy adjunct toFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2antimicrobial therapy. It potentiates antibiotic activity in vitro
(Charrier et al., 2014; Devereux et al., 2015; Fraser-Pitt et al.,
2016; Fraser-Pitt et al., 2018), as well as in murine models of
infection (Fraser-Pitt et al., 2018). Oral cysteamine bitartrate,
adjunct to SOCT, resulted in statistically significant
improvements in patient reported outcome measures and
biomarkers of inflammation and infection including reduced
white blood cell count, and CRP in patients experiencing an
infectious pulmonary exacerbation (Devereux et al., 2020).
Cysteamine may also stimulate autophagy, and reduce
proteostasis, and some groups have shown that this increases
trafficking of the cystic fibrosis transmembrane conductance
regulator (CFTR) to the plasma membrane (De Stefano et al.,
2014), although other groups have questioned this (Armirotti
et al., 2019). Cysteamine has been demonstrated to improve the
clearance of intracellular pathogens including P. aeruginosa and
Burkholderia cenocepacia from CF macrophages (Ferrari et al.,
2017; Shrestha et al., 2017; Shrestha et al., 2020). Cystic fibrosis
has recently seen a paradigm shift in terms of care with the
introduction of combinatorial modulator therapies which
address the underlying cause of the condition (Middleton
et al., 2019). Nonetheless, infectious exacerbations and
infection remain as major challenges in CF clinical care and
there is still a critical need for novel and effective interventions
that target CF symptomology. The broad-spectrum antibiotic
potentiation, mucolytic activities, and anti-inflammatory
properties of cysteamine may be of benefit to all CF genotypes.
Cysteamine interferes with the REDOX balance of the
bacterial cell through conversion to the disulphide cystamine,
which depletes intracellular NADPH and cellular reducing
power. It can also disrupt the metabolism of P. aeruginosa, and
it was noted that sub-lethal concentrations of cysteamine could
sensitise it to other antimicrobial agents. Cysteamine has a
marked effect on pigment production in numerous strains, and
the export of pyomelanin from B. cenocepacia (Fraser-Pitt et al.,
2018). Cysteamine is a highly reactive small molecule, so the
precise bacterial cell target (or more likely, targets) that are
responsible for such pleiotropic activity remain to be elucidated.
As P. aeruginosa is a versatile pathogen with a highly flexible
metabolism (Dolan et al., 2020), extensive metabolic redundancy
can hinder the identification of the precise target of
antimicrobials used against this organism. Here we explored
further the mechanisms of cysteamine-mediated interference in
bacterial metabolism and undermining of virulence traits of
P. aeruginosa.
Cysteamine has long been known to inhibit the glycine
cleavage system found in the mitochondria of eukaryotic cells
(Yudkoff et al., 1981) through inhibition of the glycine cleavage
system found in the mitochondria (Hayasaka and Tada, 1983).
This multienzyme system has a role in glycine and serine
catabolism as well as the provision of methyl groups during
the biosynthesis of methionine and purines. In mammals the
system includes the P-protein, H-protein, L-protein and T-
protein - the H-protein is one of the very few lipoylated
proteins and the P-protein requires the pyridoxal phosphate
(PLP) cofactor. The system is widely evolutionarily conserved inSeptember 2021 | Volume 11 | Article 718213
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decarboxylase enzyme is exquisitely sensitive to competitive
inhibition by cysteamine with a Ki of 5 µM, which is thought
to act via interaction with PLP (Lowry et al., 1986). Cysteamine
(in common with some other aminothiols) has long been known
to react with PLP (Buell and Hansen, 1960) by forming
thiazolidine ring. It is known to interfere with PLP-dependent
enzyme kinetics (De Marco et al., 1965), and as an endogenous
molecule there has been speculation as to the biological role
(Terzouli et al., 1998). P. aeruginosa possesses two copies of
glycine dehydrogenase (decarboxylating) genes, gcvP1 and gcvP2.
The GcvP1 and GcvP2 proteins of P. aeruginosa are also PLP-
dependent enzymes and GcvP2 belongs to the gcs2 cluster
required for glycine catabolism (Lundgren et al., 2013). Glycine
is the precursor for HCN production, first demonstrated in P.
fluorescens (Laville et al., 1998), and the glycine cleavage system
has been implicated in HCN production in P. aeruginosa too
(Sarwar et al., 2016). Inhibition of glycine catabolism caused by
increases in ammonia (a product of the reaction) has been
reported to increase the abundance of the glycine substrate
which in turn raises the amount utilised to make HCN via the
gene cluster hcnABC (Yan et al., 2018).
Here, we demonstrate that cysteamine inhibits glycine
utilisation by P. aeruginosa, and that the glycine cleavage system
has unexpected inhibitory activity on HCN production. We also
show for the first time that cysteamine disrupts chemotaxis and
swarming motility which may be linked to disruption of
metabolism, but the glycine cleavage system is not the only
target. One of the most striking impacts of cysteamine
treatment on P. aeruginosa is the inhibition of pigment
production. Pseudomonas sp. produce a wide array of pigments,
including pyocyanin, a blue REDOX active compound and toxic
virulence factor. We have reported qualitative observations on
cysteamine-mediated changes in pigment production on a wide
range of P. aeruginosa strains previously (Fraser-Pitt et al., 2018)
and here we quantify the effects on pyocyanin. P. aeruginosa also
secretes the fluorescent green-yellow iron-chelating siderophore,
pyoverdine. Pyoverdine is necessary for virulence in numerous
infection models and chemical inhibitors of the production of this
siderophore have demonstrated potential in mouse models of
infection (Kang et al., 2019) therefore we also investigated the
impact of cysteamine on pyoverdine fluorescence. Whilst
inhibition of biofilm formation by cysteamine has been
demonstrated previously against a wide range of bacteria
(Charrier et al., 2014; Fraser-Pitt et al., 2016; Fraser-Pitt et al,.
2018), here we demonstrate that it can reduce exopolysaccharide
production in an alginate-producing strain and inhibits the
induction of biofilm formation by the aminoglycoside,
tobramycin. These data illustrate that cysteamine can
dysregulate multiple aspects of P. aeruginosa virulence.MATERIALS AND METHODS
Unless otherwise stated, chemicals, reagents and media were
purchased from Sigma-Aldrich (MO, USA).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3Bacterial Strains, Growth Media and
Culture Conditions
P. aeruginosa PAO1 a commonly used type strain (Holloway,
1955) was purchased from the American Type Culture
Collection. PA14 (UCBPP-PA14) is a clinical burns isolate
(Rahme et al., 1995) first sequenced in 2004 (He et al., 2004)
and representative of common clonal isolates found worldwide
in numerous disease states including CF (Wiehlmann et al.,
2007). NH57388A is a stable mucA mucoid isolate derived from
CF sputum which produces pyocyanin (Norman et al., 2016) and
NH57388B is a non-mucoid quorum-sensing deficient strain
that does not produce N-acylhomoserine lactone signalling
molecules (Hoffmann et al., 2005).
The DgcvP2 PAO1 mutant was created by PCR amplifying
flanking regions 800-1000 bp upstream and downstream of the
gcvP2 ORF. Upstream and downstream regions were then
overlapped and cloned into the suicide vector pEX19Gm using
Gibson assembly as described previously (Huang and Wilks,
2017). The resulting deletion plasmid was then transformed into
P. aeruginosa PAO1 by electroporation and selected for on LB
plates containing 50 µg/ml gentamycin. Deletion mutants were
identified via sacB mediated sucrose counter-selection and
confirmed by PCR. Primers used are described in Table S1.
Growth media included cation-adjusted Müller-Hinton broth
2 (MHB). M9 minimal media was prepared (Miller, 1972) with
20 mM carbon sources as described previously (Sarwar et al.,
2016). Growth was assessed by optical density (O.D.) of 100 µl
volumes at 625 nm over time at 37°C in 96-well flat-bottomed
plates (Thermo-Fisher, MA, USA) using a Synergy (Biotek, VT,
USA) plate reader. When not in routine use strains were
cryopreserved in 20% glycerol (80% Müller-Hinton broth) at
-80°C for long term storage.Susceptibility (MIC) and Chemotaxis
Experiments
The MIC (minimum inhibitory concentration at which 100% of
bacterial growth is prevented) of cysteamine in different media
was calculated as described using the CLSI broth microdilution
procedure M07-A10 (Wayne, 2015). The standard solid media
used to maintain strains was Müller-Hinton agar (MHA)
containing 1.5% granulated agar (Melford Laboratories, UK),
Chemotaxis swimming and swarming assessments were
performed on M9 minimal media containing 0.3% granulated
agar, and 20 mM glucose, or 0.2% w/v casamino acids +/-
cysteamine at 200 mg/L in 2-compartment plates. Overnight
cultures grown in MHB were pelleted, washed and resuspended
in M9 minimal salts to achieve uniform OD600 = 0.4 ± 0.02 and
2 µl volumes were spotted onto the plate surface in a sterile class
II containment hood prior to incubation at 37°C (Parales and
Ditty, 2018). Images were captured at 24 and 48 h using a Nikon
D5100 (Japan) at the same conditions and settings (f/5.3, 1/50 s,
ISO-1600) and a Samsung Galaxy S20 (Samsung, South Korea)
for colour images to demonstrate inhibition in pigment
production. Colony area was calculated from colony radii. The
experiment was conducted on three occasions.September 2021 | Volume 11 | Article 718213
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Supernatants and Bacterial Cell Lysates
Bacterial cultures were prepared in Müller Hinton broth of each
strain (PAO1 parent, and DgcvP2 strain) using standardised
inoculums of 1 in 150 dilution of 0.5 McFarland standard from
overnight cultures. Three 10 ml cultures of each strain were used as
controls (no exposure to cysteamine) and 3 cultures were treated
with 200 mg/L cysteamine. After 24 h at 37°C aliquots of bacterial
cultures were serially diluted to determine final cfu/ml and then
pelleted at 5,000 g for 5 min. Clarified supernatants were carefully
removed without disturbing the pellets and filter sterilised using
syringe-driven 0.22 µM PES filter and stored at -80°C prior to
analysis. Bacterial pellets were washed 1 x in ice-cold PBS and
centrifuged again before being resuspended in 1 ml sterile distilled
water and transferred to a heating block and heated at 90°C to lyse
bacteria. Lysates were also stored at -80°C prior to analysis. Glycine
concentrations were determined fluorometrically using a glycine
assay kit ab211000 (Abcam, Cambridge UK) according to the
manufacturer’s instructions on a black-walled 96-well microtitre
plate and read using Biotek Synergy plate-reader (Biotek, VT,
USA). Uninoculated Müller-Hinton broth (both treated and
untreated) were used as controls and the addition of cysteamine
did not affect the assay or the concentration of glycine in the media
which was 2871.42 ±121.63 ng/ml (standard deviation).
Qualitative Hydrogen Cyanide Detection
Volatile HCN production was determined qualitatively via
colorimetric detection using Whatman ashless 125 mm
diameter filter paper discs (Whatman, UK) cut to fit above the
surface of a two-compartment culture dish and impregnated with
a solution containing 5 mg of copper (II) ethylacetoacetate and
5 mg 4,4’methylenebis-(N,N-dimethylaniline) in chloroform
(Castric and Castric, 1983). Discs were left to dry and stored at
4°C before use. Bacterial lawns were prepared from overnight
cultures resuspended to a uniform 0.5 McFarland cell density and
seeded onto two-compartment plates containing MHA or MHA
with 200 mg/L cysteamine and allowed to dry in a class II
containment hood. HCN detection discs were overlain above
both compartments and sterile modified microfuge tube lids were
used to keep the discs from touching the culture surface and to
prevent condensation on the lids. Plates were incubated upright at
37°C. PAO1, and DgcvP2 PAO1 cultures tended to produce HCN
quicker and were examined 18 h post inoculation, whereas PA14,
and NH57388A and B were examined at 24 h. Experiments were
conducted on three occasions.
C. elegans Assessment of HCN
Mediated Paralysis
C. elegans was maintained under standard conditions (Wood,
1988). Worms were synchronised to achieve a population of
young adults using the bleaching method described by Stiernagle
(Stiernagle, 2006).
Bacteria were grown overnight on MHA, cultures were then
diluted 1:100 in MHA and spread onto new MHA plates with or
without the incorporation of cysteamine at the sub-inhibitory
concentrations indicated in the agar and cultured for a further 24 hFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4at 37°C. Bacterial lawns were overlain with nitrocellulose
membranes in a method adapted from Darby (Darby et al.,
1999). Synchronized worms were then transferred to the
nitrocellulose membrane and incubated at room temperature for
6 h. Worms were carefully lifted from the hydrophobic
nitrocellulose membrane by 100 µl M9 buffer and transferred to
optically clear 96-well flat-bottomed plates to be examined for
paralysis and scored for survival every hour, for 6 hours, by
inspection under an Axiovert 40 CFL Microscope (Zeiss,
Germany) at x 100 magnification. Worm paralysis was defined
as no movement after mechanical stimulation.
Quantification of Pyocyanin
Pyocyanin was extracted from 12 ml P. aeruginosa cultures
grown statically in MHB for 24 hours at 37°C following
inoculation with standardised 1:150 dilutions (80 µl) of 0.5
McFarland suspensions of bacterial cells +/- cysteamine at
stated concentrations. Following incubation bacterial cells were
removed by centrifugation at 5,000 g for 5 min. Supernatants
were then transferred to a fresh tube and further clarified by
passing through a 0.22 µM PES filter. Pyocyanin was extracted
via liquid phase partitioning first with chloroform and then again
with 0.2 N HCl and quantified by measuring the absorbance of
100 µl volumes on 96-well flat-bottomed plates at 520 nm using a
Synergy plate reader, concentrations were calculated using the
extinction coefficient 17.072 (Kurachi, 1958; Essar et al., 1990).
Quantification of Exopolysaccharide
Production
The effect of cysteamine on the production of exopolysaccharide
by the stable mucoid P. aeruginosa NH57388A was compared
with the non-mucoid AHL-deficient NH57388B strain.
Exopolysaccharide production was determined in a method
adapted from that devised by Ramus (1977). Each 12 ml culture
was inoculated with standardised 1:150 dilutions (80 µl) of 0.5
McFarland suspensions of bacterial cells from overnight cultures
on MHA plates and cysteamine was added to final concentrations
of 2 - 200 mg/L. Cultures were incubated statically for 120 h at
37°C. Following incubation bacterial cells were removed by
centrifugation at 5,000 g for 5 min at 4°C, 1 ml volumes were
transferred to sterile microfuge tubes and 100 µl of acidified Alcian
blue (1 mg/ml) was added which precipitates polyanionic
exopolysaccharides such as alginate. Tubes were briefly vortexed
(10 sec) to mix before further centrifugation at 5,000 g for 5 min at
4°C which pellets the precipitate. Aliquots of supernatant (100 µl)
were then transferred to clear 96-well flat-bottomed plate and
absorbance recorded at 610 nm using a Synergy plate reader. EPS
concentration is inversely proportionate to absorbance of the
unbound dye, and samples were quantified by comparison to a
standard curve prepared using known concentrations of
sodium alginate.
Biofilm Assay
Attachment of P. aeruginosa Pa14 biomass to 6-well plates
was measured using an adapted crystal violet biofilm assay
(O’Toole et al., 1999) using standardised inoculum and
MHB growth media ± cysteamine and/or tobramycin as describedSeptember 2021 | Volume 11 | Article 718213
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measured after 24 h at 37°C by transferring 100 µl of each
replicate to optically clear microtitre plates and recording
absorbance at 625 nm. Crystal violet was released from washed
surface-attached cells using 100% ethanol and 100 µl of each
replicate transferred to microtitre plates quantified at 595 nm.Fractionation of P. aeruginosa Whole Cell
Proteome Liquid Chromatography and
Electrospray Ionisation Tandem Mass
Spectrometry (LC-ESI-MS/MS) Analysis
Sample Preparation and Separation by SDS PAGE
Six separate 10 ml cultures of P. aeruginosa PAO1 in MHB were
prepared in sterile Universal tubes using single colonies grown
from frozen stock revived overnight on MHA plates. Cultures
were incubated statically for 20 hours and diluted in fresh media if
necessary, to achieve growing cultures with an optical density of
0.3 at 625 nm. Each culture was then sub-cultured 1 ml into 9 ml
of fresh MHB and incubated for 4 hours at 37°C to achieve mid-
logarithmic growth. Bacterial cells were pelleted by centrifugation
at 5,000 g for 5 min. Following this, three of these cultures were
resuspended in MHB media alone and three were resuspended in
media containing sub-inhibitory 250 mg/L cysteamine and all
cultures were incubated for a further 4 hours at 37°C. Bacterial
cells were then pelleted by centrifugation at 5,000 g for 5 min at 4°
C and washed once with ice cold PBS. Bacterial cell pellets were
resuspended and lysed in 200 µl of BugBuster (Merck Millipore,
MA, USA) containing a protease inhibitor cocktail (Complete
Mini, Roche Diagnostics GmbH, Basel, Switzerland) at the
manufacturer’s recommended concentration. Lysate protein
concentrations were determined by bicinchoninic acid (BCA)
assay (Smith et al., 1985) and equal amounts 5 mg total protein
of whole cell lysates were separated by one-dimensional sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
using a precast 4-20% gradient Tris-glycine gel. Gel was visualised
with Coomassie based EZBlue (Sigma, MO, USA) stain.LC-ESI-MS/MS Analysis
Each of 6 lanes of whole cell proteins was fractionated into 21
slices. Each slice was subjected to in-gel tryptic digestion,
reduction, alkylation and trypsinolysis, followed by reversed-
phase liquid chromatographic separation of tryptic peptides
using rapid monolithic column chromatography and ESI-MS/
MS using a fast-scanning three-dimensional ion trap tandem
mass spectrometer (Bruker Daltonics amaZon-ETD).
LC was performed using an Ultimate 3000 nano-HPLC
system (Dionex, LC-Packings) using the method described
previously (Burgess et al., 2009).
Mass spectrum peak lists for peptides and fragmentation ions
were compared with in-silico published sequence for P. aeruginosa
PAO1 utilising the Mascot™ V2.4.1 (Matrix Science) search
engine. Mascot search parameters were set in accordance with
published guidelines (Taylor and Goodlett, 2005) and to this end,
fixed (carbamidomethyl “C”) and variable (oxidation “M” and
deamidation “N,Q”) modifications were selected along withFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5peptide (MS) and secondary fragmentation (MS/MS) tolerance
values of 0.5Da whilst allowing for a single 13C isotope. Protein
identifications obtained from each of the 21 individual gel slices
per lane were compiled using the Meta-score protein compilation
feature within the ProteinScape bioinformatics platform
(Chamrad et al., 2003). From the compiled protein lists
individual protein identifications were inspected manually and
considered significant only if a) two peptides were matched for
each protein, b) peptides were represented by a sequence coverage
of >5% and c) eachmatched peptide contained an unbroken “b” or
“y” ion series represented by a minimum of four contiguous amino
acid residues. The identification or absence of a protein in each
treatment condition is only a semi-quantitative indication of
relative abundance of proteins and individual leads need to be
confirmed with further analysis.Preparation of Sterile P. aeruginosa
Conditioned Media
P. aeruginosaNH57388A (A) was cultured for 24 h at 37°C in the
presence of sub-inhibitory concentrations of cysteamine at 0, 2,
10, 20, 100 and 200 mg/L in cation-adjusted MHB (Thermo-
Fisher, MA, USA). Culture supernatants were then clarified by
centrifugation at 5,000 g for 5 min and then filter-sterilised by
passing through a 0.22 µM syringe-driven PES filter.Assessment of the Toxicity of Secreted
P. aeruginosa Factors Produced in
Conditioned Media or Sputum
in Galleria mellonella
All Galleria mellonella larvae were purchased from Live Food UK
Ltd (Rooks Bridge, UK) and, upon arrival, kept in wood shavings
at 20°C in the dark for 3 days prior to challenge. Larvae with
approximate weight of 0.25–0.30 g, which were not already
melanized were assigned randomly to the different challenge
groups or unmanipulated or vehicle control cohorts. Larvae
were surface-sterilised with 70% ethanol. Ten microlitre volumes
of vehicle control, or conditioned media was injected into the last
left proleg as appropriate for each treatment using a 100 microlitre
Hamilton syringe which was sterilized with ethanol and larvae
were placed into separate sterile petri dishes at 37°C. A
melanisation score was determined by observation over time
according to criteria described by Kay et al. (2019), adapted
from Senior et al. (2011). Insects were considered dead when
they become unresponsive to physical stimuli and turned black in
colour. The toxicity of P. aeruginosa conditioned media was
assessed with 10 larvae per treatment group. Survival was
plotted using Kaplan-Meier survival distribution method and
tested for statistical significance using Log-rank (Mantel-Cox) test.Statistical Analysis
All statistical analysis was performed using GraphPad Prism
9.0.0. software using appropriate tests outlined in in the methods
section above or in the figure legend.September 2021 | Volume 11 | Article 718213
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Cysteamine Inhibited the Utilisation of
Glycine in Pseudomonas aeruginosa
Cysteamine has a high minimal inhibitory concentration (MIC)
of 500 mg/L in glucose minimal media against P. aeruginosa
strains (Fraser-Pitt et al., 2018) and Table S2. Here we show that
200 mg/L has little effect on growth in either the DgcvP2 mutant
or PAO1 parent strain (Figure 1A). However, cysteamine
prevented the utilisation of glycine as a sole carbon source by
P. aeruginosa PAO1 (Figure 1B) as treatment with as little as 4
mg/L cysteamine completely prevented growth. As the gcs2
cluster is responsible for glycine utilisation in P. aeruginosa
and glycine decarboxylase is the target in mammalian cells we
characterised the growth of DgcvP2 mutant and PAO1 parent
strain in glucose and glycine minimal media. As expected DgcvP2
did not grow in glycine minimal media. The addition of high
sub-inhibitory concentrations of cysteamine (200 mg/L) to
growing cultures of the PAO1 parent and DgcvP2 strains in
Müller-Hinton broth caused glycine to accumulate in both the
supernatant (Figure 1C) and bacterial lysates (Figure 1D), but
significant increases were only seen in the parent strain. Levels of
glycine, in cysteamine-treated supernatants only, were above
those of uninoculated Müller-Hinton broth, indicating that
glycine is created during metabolism in this media but that it
does not ordinarily accumulate. The DgcvP2 strain had higher
mean concentrations of glycine in the untreated pellets than the
parent strain, though this was not significant (p=0.067).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6Electrospray Ionisation Tandem Mass
Spectrometry Proteome Analysis of
P. aeruginosa Exposed to Cysteamine
Whole cell proteomic analysis was conducted to examine the
effect of cysteamine-mediated blockade on glycine utilisation by
sub-inhibitory concentrations of cysteamine.
365 proteins were confidently identified by ESI tandem MS
according to criteria outlined above. Fifteen proteins were found
only in cysteamine-treated conditions across all replicates, and
66 proteins were confidently identified only in control
conditions. The remaining 284 were confidently identified in
both conditions. Table 1 lists proteins confidently identified only
in cysteamine treated P. aeruginosa cells and Table 2 shows
proteins only confidently identified in control conditions.
Although the glycine dehydrogenase (decarboxylating)
proteins encoded by gcvP1 and gcvP2 were not amongst the
proteins detected with confidence in either cysteamine treated or
controls, the neighbouring serine hydroxymethyltransferase
(GlyA2) and glycine cleavage system protein T2 (GcvT2) were
only confidently detected in cysteamine treated cells, suggesting
an increased protein abundance in this condition. The glycyl
tRNA synthetase (glyQ) was amongst the proteins found only in
the control condition.
Also of interest, the FAD-dependent NADPH:quinone
reductase, MdaB (modulator of drug activity B), was identified
only in the cysteamine treated condition. This has been implicated
in the detoxification of certain compounds and it is linked to
quinone and REDOX cycling (Adams et al., 2005). It is not knownA
B D
C
FIGURE 1 | (A) P. aeruginosa PAO1 and DgcvP2 growth over time at 37°C in M9 minimal media supplemented with 20 mM glucose with or without the addition of
200 mg/L cysteamine (n=3). (B) Only the PAO1 parent strain can grow in M9 supplemented with 20 mM glycine as the sole carbon source and 4 mg/L cysteamine
prevents growth of the parent strain on this carbon source (n=3). (C) Glycine concentrations in bacterial culture supernatants grown for 24 h in cation-adjusted
Müller-Hinton broth at 37°C with or without the addition of 200 mg/L cysteamine (n=3). Glycine levels in media alone were unaffected by cysteamine and were
calculated as 2871.42 ±121.63 ng/ml (standard deviation). **p ≤ 0.01, two-way ANOVA with Tukey’s test. ns, not significant (D) Glycine concentrations in bacterial
lysates from cultures grown for 24 h in cation-adjusted Müller-Hinton broth at 37°C with or without the addition of 200 mg/L cysteamine (n=3). *p ≤ 0.05, Two-way
ANOVA with Tukey’s test. ns, not significant.September 2021 | Volume 11 | Article 718213
Fraser-Pitt et al. Cysteamine Disrupts Pseudomonas aeruginosa Virulenceif this is involved in a shift in NADP : NADPH ratio previously
reported to be induced by cysteamine (Fraser-Pitt et al., 2018).
Chemotaxis proteins PctA, PctC, CtpH, PA4633 and PA2652
were amongst those identified only in control conditions.
Flagellin (the structural unit of the bacterial flagellum) and the
twitching motility protein PilJ, were also only detected in
the control condition. This provided the rationale to
investigate the potential for cysteamine to inhibit chemotaxis
and chemotactic swimming and swarming motility (Figure 2).
Cysteamine Inhibits HCN Production
Glycine is converted into HCN by P. aeruginosa by the
contiguous HCN synthase genes hcnABC. A blockade of
glycine cleavage by cysteamine in P. aeruginosa might be
expected to raise glycine levels, as it does when administered to
rats (Iwama et al., 1997). Mutation in the gcsR gene, a TyrR-like
enhancer-binding protein of the alternative sigma factor RpoN
(s54) which regulates the glycine cleavage system in P.
aeruginosa PAO1 (Sarwar et al., 2016), was demonstrated to
enhance HCN-dependent paralytic-killing in the Caenorhabditis
elegans model. HCN production is also known to be under the
control of the hierarchical quorum sensing system in
P. aeruginosa.
We examined the effects of cysteamine on the production of
HCN by the DgcvP2mutant and the parent PAO1We did this by
comparing the ability of PAO1 and DgcvP2 to induce paralysis in
a C. elegans model (Darby et al., 1999), and examined any effect
of the incorporation of cysteamine into the growth media on the
ability of each strain to induce paralysis (Figure 2A). We also
examined HCN production directly by incorporating sub-
inhibitory concentrations of cysteamine into agar plates seeded
with lawns of each isolate and detecting volatile HCN produced
during culture over time (Figure 2B).
Despite effective blockade of glycine utilisation by cysteamine
in P. aeruginosa at 4 mg/L (Figure 1B), the incorporation of
cysteamine (at 200 mg/L) into MHA plates surprisingly inhibits
the production of HCN, despite having no effect on bacterialFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7growth. The DgcvP2 mutant produced more HCN than the
PAO1 parent strain over the same incubation time, and
induced paralysis in C. elegans quicker than the parent strain,
probably due to increased substrate availability. Cysteamine also
dose-dependently protected C. elegans from paralysis
(Figures 2A, B).
Cysteamine also had a marked effect on chemotaxis on semi-
solid (0.3% agar) media containing glucose as the sole carbon
source. Radial growth was apparent in control conditions at 48 h
for both the parent strain and DgcvP2 and both were impacted by
the incorporation of cysteamine into the growth media, as
surface growth out from the central inoculum was reduced and
disorganised. When grown on 0.2% w/v casamino acids medium
there is evidence of swarming motility, indicated by dendritic
outgrowth from the inoculum, in both mutant and parent strain
which is inhibited by cysteamine. The impact on pigment
production was also particularly evident when grown on
casamino acids (Figure 2C). The inclusion of cysteamine also
impacted on the area of growth, with significant reductions in
growth area for both the parent strain and DgcvP2 mutant on
agar containing 0.2% w/v casamino acids at 24 and 48 h.
Cysteamine reductions in growth on 20 mM glucose were less




Exopolysaccharide (EPS) production is important for biofilm
formation which is critical for P. aeruginosa chronic infection of
the CF lung (Høiby, Ciofu and Bjarnsholt, 2010), at least three
exopolysaccharides contribute toward biofilm production,
including Psl, Pel and alginate (Reviewed by Ghafoor et al.,
2011). Cysteamine significantly inhibited the amount of EPS
secreted by mucoid P. aeruginosa strain NH57388A into (and
precipitated from) culture media and, as expected, the non-
mucoid quorum sensing mutant NH57388B produced
significantly less exopolysaccharide than NH57388A (Figure 3A).TABLE 1 | Proteins confidently identified only in the cysteamine-treated P. aeruginosa PAO1 cells according to criteria outlined by Taylor and Goodlett, 2005.
Treatment condition Accession number Protein name Locus tag Gene name Function/pathway
Cysteamine treated NP_249916.1 FAD-dependent NADPH:quinone reductase PA1225 mdaB Oxidative stress
NP_251132.1 glycine cleavage system protein T2 PA2442 gcvT2 Glycine cleavage
NP_252418.1 hypothetical protein PA3729 Uncharacterised
NP_253999.1 aldehyde dehydrogenase PA5312 pauC Polyamine catabolism
NP_251721.1 hypothetical protein PA3031 Uncharacterised
NP_253256.1 GTPase ObgE PA4566 obgE Response to stimulus
NP_254244.1 ATP synthase F0F1 subunit delta PA5557 atpH ATP synthesis coupled proton transport
NP_249578.1 acetyl-CoA synthetase PA0887 acsA Acetate utilisation
NP_254101.1 hypothetical protein PA5414 Uncharacterised
NP_251872.1 6-phosphogluconolactonase PA3182 pgl Pentose phosphate pathway
NP_250981.1 glucose-sensitive porin PA2291 oprB2/opbA Glucose uptake
NP_253007.1 hypothetical protein PA4317 Uncharacterised
NP_249540.1 thioredoxin reductase PA0849 trxB2 Removal of superoxide radicals
NP_251134.1 serine hydroxymethyltransferase PA2444 glyA2 Glycine biosynthesis, tetrahydrofolate
interconversion
NP_251992.1 hypothetical protein PA3302 Uncharacterised
NP_251148.1 hypothetical protein PA2458 UncharacterisedSeptember 2021 | Volume 11 | Article 718213










Control NP_252997.1 chemotactic transducer PA4307 pctC Chemotaxis, response to amino acid, signal transduction
NP_252999.1 chemotactic transducer PA4309 pctA Chemotaxis, response to amino acid, signal transduction
NP_254241.1 ATP synthase F0F1 subunit beta PA5554 atpD Produces ATP from ADP in the presence of a proton gradient across the
membrane. The catalytic sites are hosted primarily by the beta subunits.
NP_253259.1 octaprenyl-diphosphate synthase PA4569 ispB Isoprenoid synthesis
NP_064729.1 glycyl-tRNA synthetase subunit alpha PA0009 glyQ Translation. Transfer of glycine amino acid to nascent peptides
NP_250378.1 spermidine synthase PA1687 speE Polyamine synthesis
NP_250243.1 cytochrome C oxidase cbb3-type
subunit
PA1552 ccoP1 Electron transport chain
NP_248735.1 hypothetical protein PA0045 csgG Uncharacterised
NP_252294.1 response regulator PA3604 erdR Ethanol detoxification
NP_251020.1 hypothetical protein PA2330 Uncharacterised
NP_252750.1 thioredoxin PA4061 YbbN Glycerol ether metabolic process, cell redox homeostasis
NP_251251.1 chemotaxis transducer PA2561 ctpH Chemotaxis, detection of phosphate ion, signal transduction
NP_249783.1 flagellin type B PA1092 fliC Swimming motility
NP_249688.1 PqsB protein PA0997 pqsB Quorum sensing
NP_253277.1 cytochrome C551 peroxidase PA4587 ccpR Oxidation-reduction processes
NP_254114.1 alcohol dehydrogenase PA5427 adhA Ethanol detoxification
NP_253754.1 phosphoribosyl-ATP
pyrophosphatase
PA5067 hisE Histidine biosynthesis
NP_251985.1 HIT family protein PA3295 Uncharacterised
NP_253563.1 OsmE family transcriptional regulator PA4876 osmE Response to stimulus
NP_249102.1 twitching motility protein PA0411 pilJ Signal transduction, chemotaxis, pilin biosynthesis
NP_252082.1 nitrous-oxide reductase PA3392 nosZ Denitrification pathway
NP_250368.1 hypothetical protein PA1677 Uncharacterised
NP_248992.1 polyamine transporter PA0301 spuE Polyamine transport
NP_253335.1 uracil phosphoribosyltransferase PA4646 upp UMP biosynthesis via salvage pathway
NP_253991.1 D-amino acid dehydrogenase small
subunit
PA5304 dadA D-amino acid metabolic process, phenylalinine metabolic process
NP_252548.1 carboxylesterase PA3859 Carboxylic ester hydrolase activity
NP_248816.1 hypothetical protein PA0126 Uncharacterised
NP_252508.1 hypothetical protein PA3819 Rick_17kDa_Anti domain-containing protein
NP_251263.1 chemotaxis transducer PA2573 Signal transduction
NP_252331.1 amino acid permease PA3641 Sodium/alanine symporter
NP_253795.1 hypothetical protein PA5108 Uncharacterised
NP_249700.1 hypothetical protein PA1009 Uncharacterised
NP_249342.1 indole-3-glycerol phosphate synthase PA0651 trpC Tryptophan biosynthesis/metabolism
NP_253323.1 chemotaxis transducer PA4633 Signal transduction
NP_253619.1 50S ribosomal protein L9 PA4932 Translation
NP_253821.1 carboxyl-terminal protease PA5134 ctpA Cell envelope organisation, cell wall biogenesis, pathogenesis, protein secretion
by the type III secretion system, signal transduction
NP_252016.1 ATP-dependent Clp protease
proteolytic subunit
PA3326 clpP2 Proteolysis
NP_251816.1 heat-shock protein IbpA PA3126 ibpA Protein folding
NP_250219.1 cell division protein PA1528 zipA Division septum assembly, FtsZ-dependent cytokinesis
NP_253376.1 ferric iron-binding periplasmic protein PA4687 hitA Iron ion homeostasis
NP_252347.1 methionine aminopeptidase PA3657 map Cellular protein metabolic process
NP_253430.1 tRNA pseudouridine synthase B PA4742 truB RNA metabolic processes
NP_251543.1 outer membrane lipoprotein PA2853 oprI Outer membrane protein
NP_253085.1 nucleotide-binding protein PA4395 yajQ Unknown
NP_253132.1 bifunctional sulfate adenylyltransferase
subunit 1/adenylylsulfate kinase
PA4442 cysNC hydrogen sulfide biosynthesis
NP_250493.1 ATP-dependent protease ATP-
binding subunit ClpX
PA1802 clpX Protein folding
NP_251342.1 chemotaxis transducer PA2652 Cellular response to an organic substance, chemotaxis
NP_250759.1 carbamoyl transferase PA2069 Biosynthetic processes, nodulation
NP_250734.1 hypothetical protein PA2044 Uncharacterised
NP_249345.1 S-adenosylmethionine decarboxylase PA0654 speD Spermidine biosynthetic process
NP_250439.1 enoyl-CoA hydratase PA1748
NP_249090.1 cystathionine beta-synthase PA0399 Cysteine biosynthetic process from serine
NP_248924.1 transcriptional regulator PA0233 Regulation of transcription
NP_249020.1 hypothetical protein PA0329 Uncharacterised
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Fraser-Pitt et al. Cysteamine Disrupts Pseudomonas aeruginosa VirulenceCysteamine had a significant effect on the exopolysaccharide
secreted by both the alginate-producing NH57388A strain and
the non-mucoid NH57388B at high sub-inhibitory concentrations.
Cysteamine Inhibits the Production of
Pyocyanin and Pyoverdine
Here we quantify the effect of a range of cysteamine doses on
pyocyanin (Figure 3B) secreted by P. aeruginosa PAO1 type strain,
NH57388A alginate-producing strain and PA14 clinical strains grown
in MHB. We also demonstrate that sub-inhibitory concentrations of
cysteamine inhibit pyoverdine fluorescence (Figure 3C).
Cysteamine Reduces Tobramycin-
Mediated Biofilm Induction
Aminoglycosides are routinely used for the control of P.
aeruginosa in CF patients, including short-term parenteral
administration during pulmonary exacerbations and chronic
use as inhalation therapies. The tobramycin inhalation powder
is safe, efficacious (Geller et al., 2011; Konstan et al., 2011) and
has been adopted for routine chronic use for patients colonised
with P. aeruginosa for some time, mainly owing to superior
convenience, and therefore improved patient compliance, over
nebulised therapies (Blasi et al., 2018). Tobramycin inhalation is
known to improve lung function over time, and reduce the
exacerbation rate (Smith et al., 2018). At the same time exposure
to sub-inhibitory concentrations of tobramycin is known to
induce biofilm formation by P. aeruginosa (Hoffman et al.,
2005) including in CF isolates, independent of minimum
inhibitory concentration (MIC) and resistance status (Elliott
et al., 2010). RpoN is known to play a role in tobramycin
tolerance and biofilm formation (Lloyd et al., 2017; Viducic
et al., 2017; Shao et al., 2018).
Here we examined the effect of combining sub-inhibitory
concentrations of cysteamine and tobramycin together on
the attachment of P. aeruginosa clinical strain PA14 to polystyrene
plates using the modified crystal violet method (O’Toole, et al, 1999).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9Although sub-inhibitory concentrations of some other antibiotics
can induce biofilm formation, tobramycin was chosen due to its use
as an inhalation maintenance therapy in CF, and PA14 was selected
due to clinical relevance. Tobramycin impaired planktonic growth at
0.2 mg/L but encouraged biofilm formation, whereas cysteamine at 2
mg/L had no impact on planktonic growth at all, alone or in
combination with tobramycin at this concentration. However, the
combination of tobramycin and cysteamine significantly reduced the
biofilm formation (Figure 4). The disulfide, cystamine, had no effect
on biofilm formation at 24 h.
Cysteamine Inhibited P. aeruginosa
Virulence in G. mellonella Model
We have already demonstrated potentiation of ciprofloxacin and
tobramycin against P. aeruginosa in different murine infection
models (Fraser-Pitt et al., 2018), but the degree to which
inhibition of bacterial virulence factor production contributed
to enhanced antimicrobial efficacy is difficult to assess and was
not examined at the time. The larvae of the wax moth G.
mellonella have been developed as a non-mammalian in vivo
infection model which has now been used extensively to test
antimicrobial agents. P. aeruginosa has strain-dependent
virulence in this model, which correlates well to virulence in
mice (Jander et al., 2000). Although some P. aeruginosa virulence
mechanisms are contact-dependent, many are secreted, so we
have assessed the toxicity of sterile-filtered culture supernatants
derived from P. aeruginosa strains at equal cell densities, treated
with different sub-inhibitory concentrations of cysteamine for 20
h at 37°C prior to injection into the insect haemolymph. The
lethality of Pseudomonas infection in G. mellonella can be
extreme and varies widely between strains (Cullen et al., 2015).
Therefore, we decided to examine sterile-filtered supernatants
from cultures of P. aeruginosa, using the less virulent mucoid
strain, NH57388A
Exposure to 2, 20, 100 and 200 mg/L cysteamine significantly














Cellular response to oxidative stress
NP_253559.1 hypothetical protein PA4872 Uncharacterised
NP_250270.1 hypothetical protein PA1579 Uncharacterised
NP_251947.1 periplasmic tail-specific protease PA3257 algO/
prc
Signal transduction, proteolysis
NP_253977.1 hypothetical protein PA5290 yifB Uncharacterised
NP_253012.1 hypothetical protein PA4322 AAA domain-containing protein, ATPase activity, ATP binding




PA5425 purK IMP biosynthesis via de novo pathway
NP_249563.1 phenylalanine 4-monooxygenase PA0872 phhA Tyrosine biosynthesis, L-phenylalanine catabolism
NP_253137.1 histidinol-phosphate aminotransferase PA4447 hisC1 L-histidine biosynthesis
NP_252221.1 bacterioferritin PA3531 bfrB Intracellular sequestering of iron
NP_250946.1 paerucumarin biosynthesis protein
PvcC
PA2256 pvcC Iron chelation
NP_249644.1 thioredoxin PA0953 helX
(DsbE)
Antioxidant activity, oxidoreductase activitySeptember 2021 | Volume 11 | Article 718213
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seen at 1 h post injection.DISCUSSION
Cysteamine was found to inhibit multiple aspects of P. aeruginosa
virulence building upon previous data demonstrating antibiofilm
activity and the ability to reduce pigment production. Results
presented here demonstrate for the first time that cysteamine can
inhibit glycine utilisation in prokaryotic cells, but the links
between this metabolic disruption and virulence factor
production are not known. We also demonstrate inhibition of
HCN and exopolysaccharide production and that cysteamine (at
therapeutically achievable doses) hinders biofilm formation
induced by tobramycin.
Inhibition of Glycine Utilisation and Links
to Virulence
Cysteamine inhibits the evolutionary well-conserved glycine
cleavage system in mammalian cells. This system is found on the
inner membrane of mitochondria in mammalian cells and is
composed of H, P, L and T proteins. It has been reported thatFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 10cysteamine increases the Km for glycine and Vmax for the P-protein
(Hayasaka and Tada, 1983), and is reported to prevent both glycine
oxidation and synthesis (Yudkoff et al., 1981). P. aeruginosa PAO1
encodes two copies of gcvH, gcvP and gcvT genes and has three
copies of the serine hydroxymethyltransferase gene glyA which
converts glycine to serine and plays an important role in the
generation of one carbon units for methylation as well as (together
with serine dehydratase) conversion to pyruvate for utilisation as a
sole carbon (or nitrogen) source (Sarwar et al., 2016). The inability
to utilise glycine in the presence of small concentrations of
cysteamine (Figure 1) could be indicative of a similar blockade.
Inhibition of glycine cleavage could be expected to interfere
with bacterial C1 metabolism and methylation. The relative
abundance of methyl-accepting chemotaxis proteins (MCPs)
may be reduced by cysteamine, with the proteins CtpH, PctA,
and PctB are amongst those identified by proteomics only in
control conditions (Table 2). The same chemotaxis proteins have
been implicated in virulence by Sheng et al., 2019, which
demonstrate inhibition of these MCPs (plus CtpM and others)
by overexpression of MapZ, a c-di-GMP-dependent inhibitor of
methylation of MCPs protected mice in an intraperitoneal model
of acute infection. Generation of the second messenger c-di-
GMP is directly linked to the glycine cleavage system via serineA B C
FIGURE 2 | C. elegans paralysis assay, HCN production, and chemotaxis and motility assays. (A) Both the PAO1 parent strain and the DgcvP2 mutant induced
paralysis in C. elegans over time. The DgcvP2 mutant produced significantly higher levels of paralysis than the parent strain. Cysteamine provided dose-dependent
protection from paralysis in both mutant and parent strain, suggesting cysteamine inhibited the HCN produced by P. aeruginosa cultures. *p ≤ 0.05, **p ≤ 0.01, ***p ≤
0.001, ****p ≤ 0.0001 two-way ANOVA and Šidák’s multiple comparisons test. (B) Colorimetric detection of volatile HCN produced by P. aeruginosa PAO1 and DgcvP2
mutant grown for the same time (n=3) showed that the mutant liberated more HCN. Experiments on 2-compartment agar plates with either MHA alone (-) or
supplemented (+) with sub-inhibitory 200 mg/L cysteamine showed that HCN production in both the mutant and the parent strain were inhibited by cysteamine. (C)
Chemotactic swimming motility of both PAO1 and the DgcvP2 mutant on 0.3% M9 agar containing 20 mM glucose was inhibited by the addition of 200 mg/L
cysteamine at 48 h, as demonstrated by the abolition of concentric rings. Swarming motility, as defined by dendritic outgrowth, was also inhibited on 0.3% agar
containing 0.2% w/v casamino acids at 24 h and 48 h, and the effect on pigment production is also evident (Representative images from n=3).September 2021 | Volume 11 | Article 718213
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et al., 2018) and high levels of c-di-GMP are linked to chronic
virulence traits including exopolysaccharide production (Lee
et al., 2007; Chung et al., 2008), alginate polymerisation and
export via Alg44 (Amikam and Galperin, 2006; Merighi et al.,
2007; Oglesby et al., 2008), biofilm formation (Hickman et al.,
2005), and antibiotic efflux (Nicastro et al., 2014; Poudyal and
Sauer, 2018; Wang et al., 2018).
In the proteomics data GcvT2 and GlyA2 were only identified
in the cysteamine-treated condition (Table 1). In combination
with a lack of detectable glycyl tRNA synthetase (GlyQ) in
cysteamine treated conditions, it is tempting to speculate that
these alterations are a direct feedback response to the inhibition
of glycine decarboxylation, and the corresponding increase in
glycine abundance (Table 2). Whilst we confirmed cysteamine
has impacts on swimming and swarming chemotactic behaviours
(Figure 2) there was an equal effect on both the DgcvP2 and
parent strain. P. aeruginosa possesses two glycine cleavage
operons therefore it could be that any impact on chemotaxis in
the DgcvP2 mutant is compensated by secondary activity of
gcvP1, or that cysteamine disrupts chemotaxis via a different
mechanism. The measurement of glycine in bacterial lysates and
supernatants confirmed cysteamine-mediated disruption of
glycine utilisation as glycine was increased in cysteamine
treated PAO1 cells (Figures 1C, D). Although the increase was
only significant in the parent strain, mean increases in glycine
were seen in the mutant also, which may suggest the gcvP1 hasFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 11residual activity impaired by cysteamine treatment and this is
worthy of future investigation.
The glycine cleavage system was initially linked to the
production of pyocyanin via the TyrR-like enhancer-binding
protein (EBP) GcsR (PA2449) believed to regulate the gsc2
operon, which includes gcvH2, gcvP2, glyA2, sdaA, and gcvT2
encoding some of the proteins mentioned above found in
cysteamine-treated cells (Lundgren et al., 2013). However, this
was subsequently disproved by the same group who determined
the inhibition of pyocyanin in the initial study was due to
unrelated mutations. This study confirmed the EBP nature of
GcsR which enhances the transcriptional activity of RpoN
upstream of the gsc2 operon. As discussed above, the DgscR
strain increased the paralytic killing of C. elegans postulated to be
caused by diverting glycine into HCN production, although the
authors did not look at HCN production directly and saw no
changes in expression of hcnABC genes (Sarwar et al., 2016). Our
study shows the DgcvP2 strain does indeed produce more HCN
than the parent strain, confirming increased substrate availability
can drive increases in hcnABC conversion of glycine to HCN. It
is therefore surprising that we see cysteamine-mediated
decreases in HCN production and reduced paralysis in C.
elegans, (Figure 2) and reduced virulence in the G. mellonella
model (Figure 5) despite inhibition of glycine catabolism.
Transcriptional control of hcnABC, which converts glycine
into HCN and CO2, is complex (Figure 6). HCN formation is
greater under low oxygen tension and the anaerobic regulator ofA B
C
FIGURE 3 | Cysteamine inhibits exopolysaccharide, pyoverdine and pyocyanin production. (A) Exopolysaccharide precipitated from sterile-filtered MHB culture
supernatants of P. aeruginosa strains NH57388A and NH57388B with acidified Alcian blue following culture for 48 h at 37°C. Quantification of exopolysaccharide secreted
into culture supernatant by NH57388A mucoid strain treated with cysteamine at 2 and 200 mg/L for 48 h at 37°C. ****p ≤ 0.0001 one-way ANOVA and Dunnet’s multiple
comparison test, ns, not significant (n=3). Cysteamine had a dose-dependent inhibitory effect on exopolysaccharide secreted from mucoid NH57388A and non-mucoid
quorum sensing deficient NH57388B strains. (B) Cysteamine-mediated inhibition of pyocyanin production by P. aeruginosa strains PAO1, PA14 and NH57388A following
20 h treatment at 37°C with the concentration range shown. *p ≤ 0.05, **p ≤ 0.01, ****p = < 0.0001, One-way ANOVA and Tukey’s test (n=3). (C) Inhibition of pyoverdine
expression after 20 h growth in MHB by cysteamine at 200 mg/L in multiple strains as detected by fluorescence at 400/460 ex/em normalised to absorbance at 625 nm
and compared with quenching induced by excess iron (1 mM Fe(III)Cl3). ****p = < 0.0001, Two-way ANOVA and Tukey’s test (n=3).September 2021 | Volume 11 | Article 718213
Fraser-Pitt et al. Cysteamine Disrupts Pseudomonas aeruginosa Virulencearginine deiminase and nitrate reductase (ANR) protein is one of
a few transcriptional regulators which influence hcnABC
(Zimmermann et al., 1991; Laville et al., 1998). ANR, and the
E. coli homologue FNR, sense oxygen via an iron-sulfur cluster,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 12and DNA binding is maximal under reducing conditions (Ye
et al., 1995; Lazazzera et al., 1996), and iron availability also
impacts HCN expression via ANR which is abolished in P.
fluorescens when iron is depleted (Blumer and Haas, 2000).A
B
FIGURE 5 | (A) Cysteamine inhibited the toxicity of microbial secreted factors toward G. mellonella produced in culture. P. aeruginosa NH57388A was cultured for
24 h at 37°C in the presence of cysteamine at 0, 2, 10, 20, 100 and 200 mg/L and 10 µl volumes of sterile-filtered supernatants were injected into G. mellonella
larvae and survival recorded over 48 h. *p ≤ 0.05, **p ≤ 0.01 log-rank (Mantel-Cox) test, ns, not significant. (B) Melanisation in response to P. aeruginosa secreted
factors was rapid as illustrated by the change in melanisation score over time and inhibited by cysteamine. Scoring criteria developed by Kay et al. (2019) are as
follows: 1. No signs of melanisation, 2. Signs of nodulation and lateral line melanisation, 3. Systemic melanisation (>50%), 4. Deceased (no movement for 20 min)
with full systemic melanisation).A B
FIGURE 4 | Cysteamine and cystamine do not inhibit growth of planktonic cells (A) at 2 mg/L. Whilst sub-lethal concentrations of tobramycin (TOBI) reduced the
number of planktonic cells at 24 h (A) induced biofilm formation over the same time period (B) and this is significantly reduced by adjunct treatment with cysteamine
but not the disulfide, cystamine (n=9). ****p ≤ 0.0001 one-way ANOVA followed by Dunnet’s post-hoc analysis. ns, not significant. *p is less than or equal to 0.05.September 2021 | Volume 11 | Article 718213
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regulate HCN production in P. aeruginosa (Latifi et al., 1995;
Winson et al., 1995; Reimmann et al., 1997; Whiteley et al¸1999)
and can act in concert to maximise HCN production (Pessi and
Haas, 2000). The GacA two-component system via two
regulatory RNAs, RsmZ and RsmY, also influences HCN
expression indirectly via quorum sensing due to enhanced
expression of rhlI, or directly post-transcriptionally, by
enhancing the translation of hcnABC (Pessi and Haas, 2001).
Therefore, we have uncovered that cysteamine blocks the glycine
cleavage system and this should, in theory, increase HCN production
as shown with the DgcvP2 mutant. Instead, cysteamine must also
simultaneously act upon one or more of the P. aeruginosa global
regulatory systems to impair HCN production, despite the presumed
backup of cellular glycine. These data highlight that precursor
availability is a key cue in HCN production in P. aeruginosa, yet a
cue which is still subordinate to the additional regulatory
mechanisms detailed above. Thus, the dissection of a single, core
metabolic target of cysteamine has unexpectedly shed light into the
regulatory hierarchy of HCN production in P. aeruginosa – a vital
virulence factor in this organism.
Inhibition of Multiple Virulence
Factors by Cysteamine
Quorum sensing systems coordinate the production of various
virulence factors in P. aeruginosa including the production ofFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 13phenazines. Our previous work demonstrated inhibition of
pigment production in multiple P. aeruginosa strains and
inhibition of the export of the pigment pyomelanin in B.
cenocepacia strains (Fraser-Pitt et al., 2018). Here we used the
chloroform extraction method to confirm the dose-dependent
reduction in pyocyanin production by P. aeruginosa in response
to cysteamine. Similarly, cysteamine interferes with the production
of the fluorescent, iron-chelating pyoverdine virulence factor.
Pyoverdine production has been described as essential for
virulence in in vivo models both with mutants of type strains
(Meyer et al., 1996) and in CF isolates (Kang et al., 2019).
Anecdotal evidence from the CARE-CF-1 trial led us to also
examine the effect of cysteamine on exopolysaccharide production.
In the trial, a dominant pyomelanin-producing sputum isolate of P.
aeruginosa was mucoid at day 0, (before treatment) and non-
mucoid at day 14 following exposure to cysteamine. It is already
known that the thiol, N-acetylcysteine (already used as a mucolytic
treatment in CF), can reduce extracellular polysaccharide
production in various bacteria (Olofsson et al., 2003). Cysteamine
also demonstrated a significant, though modest, reduction in
secreted exopolysaccharide produced by the mucoid alginate-
producing NH57388A strain.
The anti-biofilm activity of cysteamine has been reported
before. High concentrations can disrupt biofilms, whereas sub-
MIC concentrations can prevent biofilms by P. aeruginosa and B.
cepacia complex strains (Charrier et al., 2014; Fraser-Pitt et al.,A
B
FIGURE 6 | The effect of cysteamine on HCN production (A) provides clues to the anti-virulence activities of cysteamine. In untreated P. aeruginosa 1. Glycine
cleavage is uninterrupted and normal levels of glycine are available as precursors for hcnABC gene cluster for the generation of HCN which is under varying levels of
regulatory control by LasR, RhlR, AlgR, MvfR and ANR. In scenario 2. inactivation of glycine decarboxylase (GcvP2) prevents glycine utilisation, and higher
concentrations of glycine are available for the synthesis of HCN by HcnABC and an increase of HCN is detected. In scenario 3. cysteamine reversibly inactivates
GcvP2 via thiazolidine formation with the cofactor PLP. More glycine is available for HCN synthesis, but less HCN synthesis occurs, indicating cysteamine also
impairs the regulation of one or more of the regulators listed above. Panel (B) summarises the anti-virulence activities reported in this manuscript.September 2021 | Volume 11 | Article 718213
Fraser-Pitt et al. Cysteamine Disrupts Pseudomonas aeruginosa Virulence2016; Fraser-Pitt et al., 2018). Here we demonstrate that
concentrations of cysteamine that are therapeutically achievable
via systemic dosing can also reduce the biofilm promoting activity
of another agent, tobramycin. This antibiotic is frequently
employed prophylactically in adults with CF known to be
colonised with P. aeruginosa to suppress their growth, but sub-
lethal concentrations of the antibiotic have long been known to
encourage biofilm formation (Hoffman et al., 2005). A recent
study (Tahrioui et al., 2019) demonstrated the adaptive response
mechanism is thought to involve extracellular DNA release, PrrF
small regulatory RNAs and quorum sensing via the pseudomonas
quinolone signal (PQS).
The results above show cysteamine was capable of disrupting
metabolism and a number of secreted virulence factors in P.
aeruginosa. This was confirmed using the G. mellonella
invertebrate model. Larvae melanised rapidly in response to P.
aeruginosa NH57388A supernatants and died within 24 h.
Cysteamine provided some protection against this toxic
response and the results were evident quickly due to the effect
on reducing melanisation at 1 h. Most deaths in the larvae
injected with supernatants from treated P. aeruginosa occurred
at 24 h with few thereafter indicating a protection from toxicity.
In conclusion, cysteamine inhibits glycine utilisation and
dysregulates virulence factor production in P. aeruginosa at
sub-inhibitory concentrations and reduces the secretion of
toxic factors by P. aeruginosa. The strategic development of
novel therapeutics which have anti-virulence properties and
operate differently to conventional antibiotics has been described
as essential for our progress in combating antimicrobial resistance
(Fleitas Martıńez et al., 2019). Compounds which can improve the
effectiveness of other agents and at the same time reduce virulence
factor production at sub-lethal concentrations are less likely to
drive the emergence of resistance (Vale et al., 2016; Munguia and
Nizet, 2017). As an endogenously producedmolecule, expressed at
sites of inflammation and infection, it maybe that cysteamine has
an underappreciated role in innate defence against infection. In
common with many innate immune effectors, it may work best in
concert with other agents, particularly at therapeutic doses where
the effects on individual virulence factors (except for the reduction
in tobramycin mediated biofilm induction) are less easy to
demonstrate. However, the ability to reduce several virulence
factors at once in this versatile pathogen likely means the whole
effect is greater than the sum of its parts. There is clearly more than
one bacterial cell target for cysteamine and given the common
effects on eukaryotic and prokaryotic glycine cleavage systems,
cysteamine will affect both the host and the pathogen. Critical
regulatory systems in P. aeruginosa are clearly disrupted by
cysteamine and a systems-based approach may be useful in
further understanding the impact of this aminothiol on
microbial virulence and metabolism. The positive impact of
cysteamine on several virulence factors in this still-common CF
pathogen combined with the multivalent properties of this
molecule (mucolysis, antibiotic-potentiation etc.) add to the
potential utility for this endogenous molecule as a therapeutic in
CF, and potentially beyond as we continue the search for agents to
tackle the antimicrobial resistance crisis.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 14DATA AVAILABILITY STATEMENT
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